STOCK TITAN
  1. Home
  2. Sec-filings
  3. PCVX
  4. [Form 4] Vaxcyte, Inc. Insider Trading Activity

Vaxcyte (NASDAQ: PCVX) director receives RSU and stock option awards

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Vaxcyte, Inc. director Carlos V. Paya reported new equity awards. He received 2,265 shares of Common Stock underlying restricted stock units (RSUs) at no cost and 11,389 stock options with a $49.56 exercise price, both granted as compensation.

The RSUs fully vest on the earlier of June 15, 2027 or the day before the next annual stockholder meeting, with delivery deferred under Vaxcyte's Nonqualified RSU Deferral Program for Non-Employee Directors. The options vest monthly on the same schedule and expire on June 15, 2036.

Following these awards, Paya directly holds 6,856 shares of Common Stock and has 5,625 shares held indirectly through a family trust.

Positive

  • None.

Negative

  • None.
Insider Paya Carlos V
Role null
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 11,389 $0.00 --
Grant/Award Common Stock 2,265 $0.00 --
holding Common Stock -- -- --
Holdings After Transaction: Stock Option (right to buy) — 11,389 shares (Direct, null); Common Stock — 6,856 shares (Direct, null); Common Stock — 5,625 shares (Indirect, By Family Trust)
Footnotes (1)
  1. Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Pursuant to the Issuer's Nonqualified RSU Deferral Program for Non-Employee Directors, the Reporting Person has deferred delivery of all of such vested RSUs to the earlier of (i) a separation from service, or (ii) a qualifying change in control. The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.
RSU grant 2,265 shares Common Stock underlying RSUs granted to director
Option grant size 11,389 options Stock options on Common Stock granted to director
Option exercise price $49.56 per share Conversion or exercise price of new stock options
Option expiration June 15, 2036 Expiration date of stock options granted
Direct common shares after awards 6,856 shares Total direct Common Stock holdings following transactions
Indirect common shares 5,625 shares Common Stock held indirectly through a family trust
restricted stock units ("RSUs") financial
"Represents the number of shares of Common Stock underlying restricted stock units ("RSUs")."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Nonqualified RSU Deferral Program for Non-Employee Directors financial
"Pursuant to the Issuer's Nonqualified RSU Deferral Program for Non-Employee Directors, the Reporting Person has deferred delivery"
separation from service financial
"deferred delivery of all of such vested RSUs to the earlier of (i) a separation from service, or (ii) a qualifying change in control."
qualifying change in control financial
"deferred delivery of all of such vested RSUs to the earlier of (i) a separation from service, or (ii) a qualifying change in control."
vest monthly financial
"The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Paya Carlos V
(Last)(First)(Middle)
C/O VAXCYTE, INC.
825 INDUSTRIAL ROAD, STE. 300
(Street)
SAN CARLOS CALIFORNIA 94070
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Vaxcyte, Inc. [ PCVX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/15/2026A2,265(1)A$06,856D
Common Stock5,625IBy Family Trust
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$49.5606/15/2026A11,389 (2)06/15/2036Common Stock11,389$011,389D
Explanation of Responses:
1. Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Pursuant to the Issuer's Nonqualified RSU Deferral Program for Non-Employee Directors, the Reporting Person has deferred delivery of all of such vested RSUs to the earlier of (i) a separation from service, or (ii) a qualifying change in control.
2. The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.
Remarks:
Carlos V. Paya, by /s/ Peter N. Efremenko, Attorney-In-Fact06/16/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Vaxcyte (PCVX) director Carlos Paya report?

Carlos V. Paya reported equity compensation awards, not open-market trades. He received 2,265 RSU-based Common Stock shares and 11,389 stock options, both granted at $0.00 per share, along with updated direct and indirect share holdings.

How many RSUs did Vaxcyte (PCVX) grant to director Carlos Paya?

Vaxcyte granted Carlos Paya 2,265 restricted stock units (RSUs) tied to Common Stock. Each RSU represents one share. These RSUs vest in full by the earlier of June 15, 2027 or the day before the next annual meeting, subject to continuous service.

What are the terms of Carlos Paya’s new Vaxcyte stock options?

Paya received 11,389 stock options with a $49.56 exercise price per share. The options vest monthly and fully vest by the earlier of June 15, 2027 or the day before the next annual meeting, and expire on June 15, 2036.

How many Vaxcyte (PCVX) shares does Carlos Paya hold after this Form 4?

After the reported awards, Paya directly holds 6,856 shares of Vaxcyte Common Stock. An additional 5,625 shares are held indirectly through a family trust, reflecting both direct and indirect ownership positions disclosed in the filing.

How do the Vaxcyte RSUs granted to Carlos Paya vest and settle?

The 2,265 RSUs vest fully by the earlier of June 15, 2027 or the day before the next annual meeting. Under Vaxcyte’s Nonqualified RSU Deferral Program, delivery is deferred until a separation from service or a qualifying change in control.

Are Carlos Paya’s Vaxcyte (PCVX) Form 4 transactions open-market buys or sells?

The transactions reported are grants and holdings, not open-market buys or sells. RSU and option awards were granted at $0.00 per share as director compensation, and one entry reflects shares held indirectly by a family trust.